Navigation Links
Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
Date:12/8/2008

Novavax's first vaccine candidate for the prevention of RSV

ROCKVILLE, Md., Dec. 8 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Dr. Trudy Morrison, PhD, Professor of Molecular Genetics and Microbiology, University of Massachusetts Medical School, will be presenting the results of a preclinical study of a vaccine candidate for the prevention of respiratory syncytial virus ("RSV") at the 2nd Vaccine Congress in Boston, MA on December 9, 2008. This study was funded by Novavax, Inc., which has exclusive rights to develop and commercialize Paramyxovirus vaccines incorporating certain Virus-Like-Particles (VLPs) under a licensing agreement with the University of Massachusetts Medical School.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), acquired ... Lakewood, Colorado . The reputable clinic will ... , PT, DPT with his staff of four clinicians. Lipkin ... Pittsburgh and brings over 10 years of experience with a ... Belmar PT marks the 10th PRN clinic in and around ...
(Date:8/8/2017)...   Second-quarter 2017 ... loss per share from continuing operations ... 16 percent to $110 million ... to $161 million Second-quarter ... operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the third quarter of 2017. ... paid on or about October 27, 2017 to stockholders of ... 2017.  Future declarations of dividends are subject to approval of ...
Breaking Medicine Technology:
(Date:8/24/2017)... ... August 24, 2017 , ... Prime candidates for home care ... a condition that needs further monitoring such as surgery, stroke, heart attack or ... such as diabetes, high blood pressure, heart/lung disease, arthritis and stroke. , ...
(Date:8/24/2017)... ... August 24, 2017 , ... DrinkingTutors.com, a startup focused on ... tutorials, or ‘drinktorials,’ are mailed directly to teenagers’ homes every week. , ... their teenagers avoid the serious risks associated with binge drinking in high school, ...
(Date:8/23/2017)... ... 2017 , ... This week the The Voss Law Firm celebrates 14 years ... the firm grew quickly and has built a reputation for excellence, trust, and accountability. ... money they deserve from their insurance companies. , The Voss Law Firm is ...
(Date:8/23/2017)... ... 23, 2017 , ... Earlier this month, the Workgroup for Electronic Data ... to create efficiencies in healthcare information exchange and a trusted advisor to the U.S. ... which featured keynote addresses by Donald W. Rucker, MD, head of the Office of ...
(Date:8/23/2017)... ... 2017 , ... The Stevie® Awards have announced the winners of the Best of the IBA ... awards competition. , Nominees in the 2017 IBAs were not able to apply for the ... the total number of awards won in the IBAs with a Gold Stevie win counting ...
Breaking Medicine News(10 mins):